Daily Cardiology Research Analysis
Analyzed 50 papers and selected 3 impactful papers.
Summary
Analyzed 50 papers and selected 3 impactful articles.
Selected Articles
1. Proxied therapeutic inhibition on sclerostin and atrial fibrillation risk.
Using Mendelian randomization integrating genetic, transcriptomic, and proteomic data, the authors show that lower circulating sclerostin—proxied via B4GALNT3 variants—causally increases bone density but also increases atrial fibrillation risk. In vitro overexpression of B4GALNT3 reduced SOST secretion, supporting the genetic instruments and proposed mechanism.
Impact: This is among the first multi-omics MR studies to causally implicate sclerostin suppression in increased atrial fibrillation risk, directly informing cardio-safety of anti-sclerostin therapies.
Clinical Implications: Patients receiving sclerostin inhibitors (e.g., romosozumab) may warrant closer rhythm surveillance, AF risk counseling, and consideration of risk–benefit in those with preexisting arrhythmia susceptibility.
Key Findings
- Polygenic overlap was observed between circulating SOST, bone mineral density, and atrial fibrillation.
- Trans-pQTLs near B4GALNT3 served as instruments: higher B4GALNT3 expression lowered circulating SOST, increased eBMD, and increased AF risk.
- In vitro B4GALNT3 overexpression significantly decreased SOST protein secretion, supporting the causal pathway.
- Genetically proxied SOST inhibition had a significant causal effect on increased eBMD and was associated with higher AF risk.
Methodological Strengths
- Large-scale, multi-omics Mendelian randomization integrating genetic, transcriptomic, and proteomic data with GWAS sample sizes up to ~1 million.
- Experimental validation showing B4GALNT3 overexpression reduces SOST secretion, strengthening causal inference.
Limitations
- Mendelian randomization relies on instrument validity and absence of pleiotropy; residual horizontal pleiotropy cannot be fully excluded.
- Trans-pQTL instruments (B4GALNT3) may not perfectly recapitulate pharmacological SOST inhibition and short-term drug effects.
Future Directions: Prospective pharmacovigilance and randomized safety studies should quantify AF incidence under anti-sclerostin therapy and test mitigation strategies (e.g., rhythm monitoring, risk stratification).
BACKGROUND: Pharmacological inhibition of sclerostin (SOST) is clinically applied to treat osteoporosis. However, large-scale randomized controlled trials have reported conflicting findings regarding the cardiovascular effects of SOST inhibition. This study aimed to evaluate whether sustained SOST inhibition, mimicked by instrumental genetic variants, is associated with the altered risk of cardiovascular diseases (CVDs). METHODS: The individual-level genomic data were obtained from the UK Biobank, including 377,585 partic
2. Association between complications and mortality after cardiac surgery: Results from the VISION Cardiac Surgery prospective cohort study.
In a 15,550-patient, 12-country prospective cohort, acute kidney injury had the largest population-attributable fraction for 30-day mortality (37%), followed by bleeding and infection (each ~12%) and postoperative myocardial injury (~10%). Findings prioritize complications with the greatest mortality contribution for prevention strategies after cardiac surgery.
Impact: This large, international prospective analysis quantifies which postoperative complications most drive mortality, offering a clear, data-driven roadmap for prevention and quality improvement.
Clinical Implications: Implement AKI prevention bundles (hemodynamic/renal protection), optimized bleeding and infection control pathways, and routine surveillance for myocardial injury to reduce early postoperative mortality.
Key Findings
- Among 15,550 cardiac surgery patients, 30-day mortality was 3.0% and 1-year mortality was 5.5%.
- Acute kidney injury occurred in 16.8% and had the highest adjusted hazard for 30-day mortality (aHR 4.47) with the largest PAF (37%).
- Bleeding (aHR 2.39, PAF 12%), infection (aHR 1.95, PAF 12%), and postoperative myocardial injury (aHR 2.01, PAF 10%) were also major contributors to early mortality.
Methodological Strengths
- Prospective, multicenter international cohort with large sample size and standardized outcome assessment.
- Use of population attributable fractions to rank complications by mortality contribution.
Limitations
- Observational design limits causal inference; residual confounding may persist.
- Heterogeneity in perioperative practices across centers and countries could influence complication rates.
Future Directions: Test targeted prevention bundles for AKI, bleeding, infection, and myocardial injury in pragmatic trials and evaluate impact on mortality and cost-effectiveness.
OBJECTIVES: The most prognostically important complications after cardiac surgery to target for prevention remain uncertain. We aimed to assess the relationship between postoperative complications and mortality at 30 days and 1 year after cardiac surgery and rank the complications by their contribution to mortality. METHODS: We completed an analysis of 15,550 patients from the Vascular Events in Surgery Patients Cohort Evaluation (VISION) Cardiac Surgery prospective cohort study, which enrolled 15,971 pat
3. Determinants and Outcomes of Late Electrical Storm in Patients Supported by Left Ventricular Assist Device.
Among 1,151 LVAD recipients, late electrical storm occurred in 4.3% at a median of 9.2 months post-implantation and was associated with markedly higher 5-year all-cause and cardiac mortality. A risk score using four independent predictors (pre-implant LVEDD ≥80 mm, non-ischemic cardiomyopathy, prior VAs, pre-implant ICD) showed good discrimination (C=0.76).
Impact: Defines the prognostic weight of late electrical storm distinct from other late VAs and delivers an actionable risk score to guide surveillance and preventive strategies in LVAD care.
Clinical Implications: High-risk patients per the Late ES-LVAD score may benefit from intensified rhythm surveillance, tailored antiarrhythmic and device strategies, and proactive substrate modification to mitigate mortality.
Key Findings
- Late electrical storm occurred in 4.3% of LVAD patients, typically ~9 months after implantation.
- Late ES independently increased 5-year all-cause mortality (aHR 2.87) and cardiac mortality (aHR 3.47), whereas late VA without ES had no prognostic impact.
- Independent predictors of late ES were LVEDD ≥80 mm, non-ischemic cardiomyopathy, prior VAs, and pre-implant ICD; the derived Late ES-LVAD score had C-statistic 0.76.
Methodological Strengths
- Large, international, multicenter cohort with long-term outcomes.
- Multivariable modeling and development of a clinically usable risk score with internal discrimination assessment.
Limitations
- Retrospective design across a long time span (2006–2019) with potential era and center effects.
- Risk score requires external validation and evaluation of interventional strategies guided by the score.
Future Directions: Prospective validation of the Late ES-LVAD score and randomized or pragmatic trials testing surveillance and prophylactic strategies in high-risk strata.
BACKGROUND: While ventricular arrhythmias (VAs) are frequent following left ventricular assist device (LVAD) implantation, the characteristics and prognostic significance of late electrical storm (ES) remain incompletely understood. OBJECTIVE: To assess the incidence and clinical impact of late ES in LVAD recipients. METHODS: This international, multicenter, retrospective study included 1,151 LVAD recipients implanted between 2006-2019. Late ES was defined as ≥3 sustained VA episodes within 24h occurrin